Outcomes in COVID-19 proxalutamide studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
death
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
death
0/75
1/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment 71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement All studies 78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement 4 proxalutamide COVID-19 studies c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome) Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
0/75
1/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment 71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
45/423
171/355
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement All studies 78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement 4 proxalutamide COVID-19 mortality results c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 97%
0.03 [0.00-0.47]
0/134
17/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 90%
0.10 [0.01-1.84]
0/75
5/102
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0043
Early treatment 95%
0.05 [0.01-0.40]
0/209
22/236
95% improvement All studies 95%
0.05 [0.01-0.40]
0/209
22/236
95% improvement 2 proxalutamide COVID-19 mechanical ventilation results c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0043
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 91%
0.09 [0.03-0.27]
hosp.
3/134
35/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 86%
0.14 [0.03-0.60]
hosp.
2/75
19/102
Kintor (DB RCT) 50%
0.50 [0.15-1.65]
hosp.
4/365
8/365
Tau​2 ​ = 0.47, I​2 ​ = 53.4%, p = 0.002
Early treatment 81%
0.19 [0.07-0.54]
9/574
62/601
81% improvement Cadegiani (DB RCT) 33%
0.67 [0.54-0.82]
hosp. time
423 (n)
355 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0001
Late treatment 33%
0.67 [0.54-0.82]
0/423
0/355
33% improvement All studies 72%
0.28 [0.10-0.81]
9/997
62/956
72% improvement 4 proxalutamide COVID-19 hospitalization results c19 early.org/x Jun 2023Tau​2 ​ = 0.87, I​2 ​ = 80.5%, p = 0.019
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
death
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
death
0/75
1/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment 71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement All studies 78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement 4 proxalutamide COVID-19 serious outcomes c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome) Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani (DB RCT) 45%
0.55 [0.49-0.62]
no recov.
423 (n)
355 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 45%
0.55 [0.49-0.62]
0/423
0/355
45% improvement All studies 45%
0.55 [0.49-0.62]
0/423
0/355
45% improvement 1 proxalutamide COVID-19 recovery result c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Kintor (DB RCT) 74%
0.26 [0.13-0.51]
viral+
n/a
n/a
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Early treatment 74%
0.26 [0.13-0.51]
74% improvement All studies 74%
0.26 [0.13-0.51]
74% improvement 1 proxalutamide COVID-19 viral clearance result c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
death
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
death
0/75
1/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment 71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement All studies 78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement 4 proxalutamide COVID-19 Randomized Controlled Trials c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome) Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
0/75
1/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
0/365
1/365
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.18
Early treatment 71%
0.29 [0.05-1.75]
0/574
4/601
71% improvement Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
45/423
171/355
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement All studies 78%
0.22 [0.17-0.30]
45/997
175/956
78% improvement 4 proxalutamide COVID-19 RCT mortality results c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
death
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.3
Early treatment 80%
0.20 [0.01-4.13]
0/134
2/134
80% improvement Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
death
45/423
171/355
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Late treatment 78%
0.22 [0.16-0.30]
45/423
171/355
78% improvement All studies 78%
0.22 [0.16-0.30]
45/557
173/489
78% improvement 2 proxalutamide COVID-19 peer reviewed studies c19 early.org/x Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p < 0.0001
Effect extraction pre-specified (most serious outcome) Favors proxalutamide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
McCoy (DB RCT) 80%
0.20 [0.01-4.13]
death
0/134
2/134
censored, see notes Improvement, RR [CI] Treatment Control McCoy (DB RCT) 97%
0.03 [0.00-0.47]
ventilation
0/134
17/134
censored, see notes McCoy (DB RCT) 91%
0.09 [0.03-0.27]
hosp.
3/134
35/134
censored, see notes Cadegiani (DB RCT) 63%
0.37 [0.02-8.85]
death
0/75
1/102
Cadegiani (DB RCT) 90%
0.10 [0.01-1.84]
ventilation
0/75
5/102
Cadegiani (DB RCT) 86%
0.14 [0.03-0.60]
hosp.
2/75
19/102
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/365
1/365
Kintor (DB RCT) 50%
0.50 [0.15-1.65]
hosp.
4/365
8/365
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/360
1/361
Kintor (DB RCT) 71%
0.29 [0.06-1.37]
hosp.
2/360
7/361
Kintor (DB RCT) 67%
0.33 [0.01-8.16]
death
0/346
1/347
Kintor (DB RCT) 92%
0.08 [0.01-0.79]
hosp.
0/346
6/347
Kintor (DB RCT) 74%
0.26 [0.13-0.51]
viral+
n/a
n/a
Cadegiani (DB RCT) 78%
0.22 [0.16-0.30]
death
45/423
171/355
Cadegiani (DB RCT) 79%
0.21 [0.15-0.30]
death
34/423
138/355
Cadegiani (DB RCT) 45%
0.55 [0.49-0.62]
no recov.
423 (n)
355 (n)
Cadegiani (DB RCT) 55%
0.45 [0.39-0.52]
no recov.
423 (n)
355 (n)
Cadegiani (DB RCT) 33%
0.67 [0.54-0.82]
hosp. time
423 (n)
355 (n)
Proxalutamide COVID-19 outcomes c19 early.org/x Jun 2023Favors proxalutamide
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
